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Disialoganglioside GD2 is an important target on several pediatric and adult cancer types
including neuroblastoma, retinoblastoma, melanoma, small-cell lung cancer, brain tumors,
sarcomas, and cancer stem cells. We have utilized structural and computational meth-
ods to refine the framework of humanized monoclonal antibody 3F8, the highest affinity
anti-GD2 antibody in clinical development. Two constructs (V3 and V5) were designed to
enhance stability and minimize potential immunogenicity. Construct V3 contained 12 point
mutations and had higher thermal stability and comparable affinity and in vitro tumor cells
killing as the parental hu3F8. Construct V5 had nine point mutations to minimize poten-
tial immunogenicity, but resulted in weaker thermal stability, weaker antigen binding, and
reduced tumor killing potency. When construct V3 was combined with the single point
mutation HC:G54I, the resulting V3-Ile construct had enhanced stability, antigen binding,
and a nearly sixfold increase in tumor cell killing. The resulting product is a lead candidate
for clinical development for the treatment of GD2-positive tumors.
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INTRODUCTION
GD2 is a ganglioside expressed in several pediatric and adult can-
cer types and has been actively targeted by cancer immunotherapy
approaches (see Ref. (1) for recent review). GD2 is a member
of the b-series gangliosides, which are normally expressed during
fetal development and are highly restricted to the central ner-
vous system in healthy adults, with low levels of expression on
peripheral nerves and skin melanocytes (2). GD2 has been found
to be expressed in neuroectoderm-derived tumors and sarcomas,
including neuroblastoma, retinoblastoma, melanoma, small-cell
lung cancer, brain tumors, and sarcomas (3–5). Recent evidence
has also shown that GD2 can be found on breast cancer stem cells
(6, 7), as well as on neuroectodermal (8) and mesenchymal stem
cells (9, 10).
Because of its surface expression on tumor cells and restricted
normal expression in the brain and low levels in the periphery,
GD2 has been an ideal target for the development of mono-
clonal antibodies (MoAbs), which cannot cross the blood–brain
barrier. Several anti-GD2 antibodies have been developed and
tested in the clinic over the past 20 years, primarily in pedi-
atric neuroblastoma patients. 3F8 was the first anti-GD2 MoAb
to be tested in patients with neuroblastoma (3, 11, 12). MoAb
3F8 is a murine IgG3 with the highest reported affinity for
GD2 (K D= 5 nM) (13). It binds specifically to the pentasac-
charide epitope on GD2. Phase II clinical data have demon-
strated that 3F8 when combined with the cytokine GM-CSF
can significantly improve the survival of high-risk stage 4 chil-
dren with metastatic neuroblastoma (14). Murine 3F8 was more
recently humanized (hu3F8) based on complementarity deter-
mining region (CDR) grafting (13), and is currently in Phase
I clinical trials (clinical trials.gov NCT01419834, NCT01757626,
and NCT01662804).
We have previously solved the crystal structure of murine 3F8 to
1.65 Å resolution (protein data bank 3VFG) and used completely
in silico methods to find a single point mutation (HC:G54I) that
could significantly enhance the antibody-dependent cell-mediated
cytotoxicity (ADCC) of hu3F8 (15). Based on computational
modeling, we have developed two additional hu3F8 frameworks,
named V3 and V5, which were designed to optimize the properties
of hu3F8. More specifically, V3 was designed to maximize stability
and V5 was designed to minimize potential immunogenicity. We
present here the computational methods used to derive the hu3F8
V3 and V5 frameworks along with their experimental properties
of antigen binding, thermal stability, and in vitro ADCC.
MATERIALS AND METHODS
MOLECULAR MODELING
Molecular modeling, energy calculations, and image renderings
were done using Discovery Studio 4.0 (Accelrys, San Diego, CA,
USA). The crystal structure of m3F8 Fab (pdb 3VFG) and the
homology model of hu3F8 Fab were simulated using CHARMm
(CHemistry at Harvard Molecular mechanics) force fields, and
the effects of point mutations were calculated from the difference
between the folding free energies of the mutated structure and
the parental protein. Generalized Born approximation was used
to account for the effect of the solvent and all electrostatic terms
were calculated as a sum of coulombic interactions and polar con-
tributions to the solvation energy. A weighted sum of the van der
Waals, electrostatic, entropy, and non-polar terms was calculated
for each point mutation.
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CONSTRUCTION AND EXPRESSION OF hu3F8 CONSTRUCTS
Humanized 3F8 genes were synthesized for CHO cells (Blue Heron
Biotechnology or Genscript) as previously described (13). Using
the bluescript vector, these heavy and light chain genes of hu3F8
were transfected into DG44 cells and selected with G418 (InVit-
rogen, CA, USA). Hu3F8 producer lines were cultured in Opticho
serum free medium (InVitrogen) and the mature supernatant
was harvested as previously described (13). Protein A affinity col-
umn was pre-equilibrated with 25 mM sodium citrate buffer with
0.15 M NaCl, pH 8.2. Bound hu3F8 was eluted with 0.1 M cit-
ric acid/sodium citrate buffer, pH 3.9 and alkalinized (1:10 v/v
ratio) in 25 mM sodium citrate, pH 8.5. It was passed through
a Sartobind-Q membrane and concentrated to 5–10 mg/mL in
25 mM sodium citrate, 0.15 M NaCl, pH 8.2.
THERMAL STABILITY MEASUREMENTS
The thermal stabilities of MoAbs were measured by differen-
tial scanning fluorimetry using the Protein Thermal Shift assay
(Life Technologies). MoAbs (0.2 mg/mL) were mixed with Sypro
Orange dye and fluorescence was monitored using a StepOne-
Plus quantitative PCR machine (Applied Biosystems) with a 1%
thermal gradient from 25 to 99°C. Data were analyzed using Pro-
tein Thermal Shift Software (Applied Biosystems) to calculate
the Tm using the derivative method. Fab and F(ab’)2 prepara-
tions of hu3F8 were used to correctly assign the Fab peak for the
hu3F8 samples. All samples were prepared in triplicate. Statistical
significance was calculated using a student’s T test.
BINDING KINETICS BY SURFACE PLASMON RESONANCE
In vitro binding kinetics were measured using Biacore T-100
(GE Healthcare) as previously described (13). In brief, ganglio-
sides were directly immobilized onto the CM5 sensor chip via
hydrophobic interaction. Purified anti-GD2 MoAbs were diluted
in HBS-E buffer containing 250 mM NaCl at increasing concen-
trations (50–1600 nM) prior to analysis. Samples (60µL) were
injected over the sensor surface at a flow rate of 30µL/min over
2 min. Following completion of the association phase, dissocia-
tion was monitored in HBS-E buffer containing 250 mM NaCl
for 300 s at the same flow rate. At the end of each cycle, the sur-
face was regenerated using 50µL 20 mM NaOH at a flow rate of
50µL/min over 1 min and 100µL 4 M MgCl2 at a flow rate of
50µL/min over 2 min. The data were analyzed by the bivalent
analyte model and default parameter setting for the rate constants
using the Biacore T-100 evaluation software, and the apparent
association on rate constant (kon), dissociation off rate constant
(koff), and equilibrium dissociation constant (K D= koff/kon) were
calculated.
ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY BY
51CHROMIUM RELEASE
Human neuroblastoma cell line LAN-1 was provided by Dr. Robert
Seeger (Children’s Hospital of Los Angeles). LAN-1 cells were
grown in F10 RPMI 1640 medium supplemented with 10% fetal
bovine serum (Hyclone, South Logan, UT, USA), 2 mM glutamine,
100 U/mL penicillin, and 100µg/mL streptomycin at 37°C in a
5% CO2 incubator. ADCC assays were performed using NK-92MI
cells stably transfected with the human CD16 Fc receptor as previ-
ously described (13). LAN-1 target cells were detached with 2 mM
EDTA in Ca2+ Mg2+ free PBS and washed in F10, before radiola-
beling with 51Cr for ADCC assays. All samples were prepared in
triplicate. Dose–response curves were fitted by non-linear regres-
sion to a sigmoidal dose–response (variable slope) model, using
GraphPad Prism software, to allow for determination of EC50. For
comparison of curves, best-fit values for EC50 were analyzed for
significance using F tests.
RESULTS
DESIGN OF CONSTRUCTS V3 AND V5
Constructs V3 and V5 (see Figure 1) were designed utilizing com-
pletely in silico methods, based on both the crystal structure of
murine 3F8 Fab (pdb 3VFG) and a homology model of hu3F8 Fab
that was built using MODELLER followed by CHARMm energy
minimizations. The original hu3F8 that was built by CDR graft-
ing methods utilized the human germline sequences IGHV3-33
for the heavy chain template and IGKV3-15 for the light chain
template (www.imgt.org). These same templates were utilized in
FIGURE 1 | Mutations generated based on in silico modeling.
(A) Location of 12 point mutations in hu3F8 for construct V3. (B) Location of
nine point mutations in hu3F8 for construct V5. Full listing of mutational
energies can be found inTables 1 and 2.
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deciding which mutations to incorporate into V3 and V5, in order
to minimize potentially immunogenic sequences.
Table 1 shows the 12 mutations that were incorporated into
hu3F8 resulting in construct V3, along with their predicted muta-
tional energies. In silico mutagenesis was done on every potential
humanizing mutation in the murine 3F8 structure that was not
directly predicted to be involved in antigen recognition, based on
our previous 3F8:GD2 docked model (15). In addition, poten-
tial back mutations and humanizing mutations were analyzed in
the homology model of hu3F8. Table 1 shows both of these sets
of calculations. In choosing which mutations to incorporate into
construct V3, more emphasis was placed in the first set of cal-
culations for stabilizing the murine 3F8 structure, since this was
the experimentally verified high-resolution crystal structure, in
comparison to the homology model of hu3F8, which can con-
tain inherent error. Another consideration in placing emphasis
on the native structure of murine 3F8 was the fact that murine
3F8 had consistently shown higher antigen-binding affinity than
hu3F8 (13).
The analysis showed that five mutations that were made in the
original hu3F8 were destabilizing, and so for construct V3, those
mutations were reverted back to the murine sequence (LC:E1S,
LC:T10F, LC:S12L, HC:V11L, and HC:S21T). Two additional back
mutations were made (LC:P40A and LC:Q100G) because they
involved Gly or Pro residues that can affect protein backbone
conformation. To offset the potential immunogenicity of these
seven back mutations in the V3 construct, five humanizing muta-
tions were added (LC:K24R, LC:S56T, LC:V58I, HC:I20L, and
HC:M89V), which had either enhanced stability or had a neg-
ligible effect (< 0.5 kcal/mol). Two of these mutations involved
mutating CDR residues (LC:K24R and LC:S56T). The net result
of all 12 mutations was predicted to have a stabilizing mutational
energy of -3.55 kcal/mol to the murine 3F8 structure. However,
this same set of mutations in the model of hu3F8 was predicted to
have a destabilizing mutational energy of +4.61 kcal/mol.
Table 1 | Mutation energies associated with the design of constructV3.
Mutation Location Mutation
energy
(kcal/mol)
in m3F8 Fab
Mutation
energy
(kcal/mol)
in hu3F8 Fab
Resulting
phenotype
LC: E1S Framework −0.48 +0.28 Murine
LC: T10F Framework +0.17 −0.95 Murine
LC: S12L Framework −1.26 +0.79 Murine
LC: K24R CDR L1 −0.21 −0.17 Human
LC: P40A Framework +0.22 +1.41 Murine
LC: S56T CDR L2 −0.05 +0.04 Human
LC: V58I Framework −0.64 +0.01 Human
LC: Q100G Framework +1.06 +2.94 Murine
HC: V11L Framework −1.61 +0.99 Murine
HC: I20L Framework +0.43 −0.86 Human
HC: S21T Framework −0.68 +0.42 Murine
HC: M89V Framework −0.50 −0.29 Human
Net result −3.55 +4.61
Table 2 shows the nine point mutations were incorporated into
hu3F8 to make construct V5, in an effort to minimize potential
immunogenicity. In addition to the five humanizing mutations
from construct V3 (LC:K24R, LC:S56T, LC:V58I, HC:I20L, and
HC:M89V), construct V5 also includes four additional human-
izing mutations (HC:A62S, HC:F63V, HC:M64K, and HC:S65G),
which are located on CDR H2. These four CDR residues were pre-
dicted to be a part of a potentially moderate affinity MHC class
II T-cell epitope, which can result in enhanced immunogenicity
(as identified using the NN-align method on the Immune Epitope
Database (http://www.iedb.org/). The net mutational energy of all
nine mutations in construct V5 was predicted to be a moderately
destabilizing +1.62 kcal/mol for the murine 3F8 structure, and
+0.90 kcal/mol for the hu3F8 model.
Potential immunogenicity of constructs V3 and V5 as com-
pared to hu3F8 was analyzed using the T20 score analyzer (16), a
new in silico tool that can predict the“humanness”content of anti-
body variable regions derived from a database of ~38,700 human
antibody variable sequences. Table 3 shows the T20 scores for
hu3F8, V3, and V5. As expected, the net two additional murine
mutations in V3 compared to hu3F8 resulted in slightly lower T20
scores, and the net nine humanizing mutations in V5 resulted
in higher T20 scores, a characteristic of low immunogenicity
MoAbs.
Table 2 | Mutation energies associated with the design of constructV5.
Mutation Location Mutation
energy
(kcal/mol)
in m3F8 Fab
Mutation
energy
(kcal/mol)
in hu3F8 Fab
Resulting
phenotype
LC: K24R CDR L1 −0.21 −0.17 Human
LC: S56T CDR L2 −0.05 +0.04 Human
LC: V58I Framework −0.64 +0.01 Human
HC: I20L Framework +0.43 −0.86 Human
HC: A62S CDR H2 −0.24 −0.50 Human
HC: F63V CDR H2 +1.91 +1.80 Human
HC: M64K CDR H2 +0.10 −0.23 Human
HC: S65G CDR H2 +0.82 +1.10 Human
HC: M89V Framework −0.50 −0.29 Human
Net result +1.62 +0.90
Table 3 | Humanness content based onT20 score analyzer (16).
Domain Construct T20 (CDR+ framework) T20 (framework)
VL hu3F8 76.0 84.8
VL V3 74.8 80.2
VL V5 78.9 85.9
VH hu3F8 71.6 82.2
VH V3 71.6 82.0
VH V5 76.4 84.3
Scale is on the order of 0–100, with 100 being the most human in sequence.
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Table 4 |Thermal stability of hu3F8 constructs.
Construct FabTm (°C) ∆Tm Fab (°C) p-Value
hu3F8 73.6±0.3
V3 75.4±0.5 1.8 0.006
V3-Ile 75.1±0.1 1.5 0.001
V5 64.5±0.3 −9.1 <0.001
Samples were prepared in triplicate and measured by differential scanning
flourimetry. Values are shown as mean± standard deviation.
FIGURE 2 | Composite surface plasmon resonance sensorgram of the
binding hu3F8,V3,V3-Ile, andV5 to ganglioside GD2. Analysis of binding
kinetics is shown inTable 5. Full sensorgrams are presented in Figure S1 in
Supplementary Material.
THERMAL STABILITY
The thermal stability of hu3F8, V3, and V5 was measured using
differential scanning fluorimetry (see Table 4). The Fab domain of
construct V3, which was designed to be more stable, had a nearly
2°C increase in Tm compared to hu3F8 (p= 0.006). Construct V5,
on the other hand, had substantially lower thermal stability (9°C
lower Tm than hu3F8). Based on the enhanced stability, V3 was
chosen as a lead candidate, and the HC:G54I mutation, which we
had previously shown to enhance tumor cell killing, was incorpo-
rated to make construct V3-Ile. The measured thermal stability of
V3-Ile was nearly identical to V3.
ANTIGEN BINDING KINETICS
The GD2 binding kinetics of hu3F8, V3, V3-Ile, and V5 were mea-
sured by surface plasmon resonance (see Figure 2 for normalized
composite sensorgram, Figure S1 in Supplementary Material for
complete sensorgrams, and Table 5 for analysis). Construct V3
(11.5 nM K D) had similar binding properties to hu3F8 (9.1 nM
K D). Construct V5, on the other hand, had an almost twofold
loss in binding (19.1 nM K D), which may have resulted from the
additional CDR mutations and/or the weakened thermal stability.
Construct V3-Ile had the highest GD2 affinity (3.7 nM K D). Inter-
estingly, this enhancement in affinity is higher than what we had
previously observed with the HC:G54I mutation in the parental
hu3F8 framework.
Table 5 | Analysis of binding kinetics measured by surface plasmon
resonance.
Construct K on (S-1M-1) K off (S-1) KD (nM)
hu3F8 1.15×105 1.04×10-3 9.1
V3 1.09×105 1.25×10-3 11.5
V3-Ile 1.28×105 0.48×10-3 3.7
V5 1.73×105 3.30×10-3 19.1
Kon and Koff were determined from individual sensorgrams, shown in Figure S1
in Supplementary Material.
FIGURE 3 | In vitro antibody-dependent cell-mediated cytotoxicity
assay of human neuroblastoma LAN-1 target cells. Antibodies were
applied to LAN-1 cells in the presence of NK-92MI cells stably transfected
with the human CD16 Fc receptor, at an effector:target ratio of 20:1.
Samples were prepared in triplicate, and cytotoxicity was measured by
51chromium release. Values are shown as mean± standard error.
IN VITRO ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
Antibody-dependent cell-mediated cytotoxicity assays were
done to test the effectiveness of hu3F8, V3, V3-Ile, and V5
on human neuroblastoma LAN-1 cells (see Figure 3 and
Table 6). Cytotoxicity of an isotype matched non-targeting
control is shown in Figure S2 in Supplementary Mater-
ial. Consistent with the antigen binding data, V3 had sim-
ilar binding to hu3F8 (EC50 of 3.83± 0.51× 10-3 µg/mL for
V3 compared to EC50 of 2.61± 0.48× 10-3 µg/mL for hu3F8,
p= 0.1138). Construct V5 had significantly weaker killing (EC50
of 6.55± 1.45× 10-3 µg/mL, p= 0.0025). Construct V3-Ile had
the highest level of killing (EC50 of 0.46± 0.08× 10-3 µg/mL), a
nearly sixfold increase in killing relative to hu3F8 (p< 0.0001) and
eightfold increase over its parental V3.
DISCUSSION
Aberrant glycosylation has long been considered to be a hallmark
of cancer (17). Ganglioside markers such as GD2 have become an
attractive target in recent years because of the number of tumor
types and cancer stem cells that express it on their surface, as
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Table 6 | Analysis of in vitro antibody-dependent cell-mediated
cytotoxicity of neuroblastoma LAN-1 cells.
Construct EC50 (×10-3 µg/mL) Relative potency p-Value
hu3F8 2.61±0.48 1
V3 3.83±0.51 0.7 0.1138
V3-Ile 0.46±0.08 5.7 <0.0001
V5 6.55±1.45 0.4 0.0025
Samples were prepared in triplicate. Values are shown as mean± standard error.
well as GD2’s restricted expression in normal tissue. Monoclonal
antibody 3F8 is a lead therapeutic candidate in this area, and its
derivatives are being tested in a number of different targeting
strategies including bispecific T-cell engaging antibodies, pre-
targeted radio-immunotherapy, drug/toxin conjugates, nanopar-
ticles, and even chimeric antigen receptors for use in adoptive cell
therapy.
As in all antibody therapeutics, in vivo efficacy is affected by
antigen affinity, antibody stability, immunogenicity, as well as a
number of serum stability and pharmacokinetics related factors.
In this study, we have investigated a structural and computational
approach to refine the stability and to reduce computationally
predicted immunogenicity of a humanized form of the anti-GD2
MoAb 3F8. By introducing site-specific mutations based on force-
field simulations of the antibody crystal structure, we generated
construct V3, which had significantly higher thermal stability, and
comparable antigen binding and in vitro ADCC.
We have additionally attempted to minimize potential
immunogenicity in designing construct V5, which had major
mutations to CDR residues to eliminate a predicted T-cell epitope.
Immunogenicity is a major component of clinical efficacy. A large
percentage of neuroblastoma patients treated with the murine
3F8 developed a human anti-mouse antibody response, limiting
repeated administrations of this antibody. In the case of designing
construct V5, however, the mutations were too stringent, resulting
in lowered thermal stability, weaker antigen binding, and weaker
tumor cell killing. Finally, we combined our stability enhanced V3
construct with the cytotoxicity enhancing mutation (HC:G54I),
which resulted in enhanced stability, antigen binding, and in vitro
tumor cell killing, compared to the parental hu3F8.
While there are several examples of using computational meth-
ods to enhance the properties of antibodies [see Ref. (18) for
review], there are few examples of using site-specific in silico based
framework mutations to enhance thermal stability profiles. Wang
and Duan (19) did suggest mutations to the VH–VL interface of
anti-VEGF single-chain variable fragment (scFv) to enhance ther-
mal stability based on molecular dynamics simulations, but with
no experimental validation. We have recently shown that disulfide
stabilization at the VH–VL interface of the anti-GD2 scFv 5F11
in the context of a GD2xCD3 tandem scFv bispecific antibody
resulted in a 10°C increase in thermal stability and a nearly 150-
fold increase in tumor killing potency (20). Enhancing thermal
stability can also lead to less aggregation and less immunogenicity.
Liu et al. (21) have shown that disulfide stabilization of an anti-
CD22 antibody–toxin fusion protein resulted in enhanced thermal
stability and less immunogenicity in mice. What is novel and less
obvious in this investigation is that we used in silico predictions to
make site-specific framework mutations which resulted in a nearly
2°C increase in thermal stability to the V3 framework, and when
combined with a cytotoxicity enhancing mutation also derived by
in silico methods, resulted in enhancement of both antigen binding
affinity and tumor cell killing potency. In fact, we had previously
shown that cytotoxicity enhancing Ile mutation (HC:G54I) had
nearly the same binding to GD2 as the parental hu3F8 (15), but
when the same mutation was inserted into the more stable V3
framework in this investigation, there was a greater than twofold
enhancement to GD2 binding. We have therefore demonstrated
that structural and computational methods can be used to refine
MoAbs that bind to complex carbohydrate targets such as GD2,
with further in vivo validation necessary to progress toward clinical
development.
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